Search results
Found 18567 matches for
Prevalence of Pathogenic Antibodies in Psychosis 1 (PPiP1) 2013-2014
PPiP1 study aimed to investigate the prevalence of antibodies against neuronal cell surface targets in patients experiencing their first episode of psychosis in comparison with healthy participants in the control group. The immune system normally controls our ability to fight infection. If the immune system goes wrong it may cause diseases known as ‘autoimmune’ diseases. These diseases involve autoimmune ‘antibodies’ that target healthy parts of the body, instead of infections. We can detect these antibodies using blood tests. We are specifically interested in antibodies that may be the cause of symptoms of psychosis or schizophrenia. During the study we worked with NHS Mental Health services across England to investigate the prevalence of these antibodies in people with first episode of psychosis.
Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
The PPiP2 study aims to investigate the prevalence of autoimmune antibodies in patients with psychosis and identify people with psychosis and anti-neuronal membrane antibodies to take part in the SINAPPS2 trial.
PPiP2 Study
PPiP2 is a cross-sectional study conducted in over 40 NHS mental health trusts, across England and Scotland. It uses live-based assay to test serum of study participants with psychosis for NMDAR, LGI1, GABA-A and CASPR2. PPiP2 will continue to recruit study participants until the end of November 2027.
Press Enquiries
For all press enquiries, please contact
PPiP2 Research Teams in participating NHS Trusts
Please email researchers in a NHS trust where you receive mental health care. If your NHS trust is not in the list email ppip@psych.ox.ac.uk